RE:RE:Roche's oral selective oestrogen degrader fails in BCIn 2021 Roche also announced that the Swiss company would be walking away from its gene therapy collaboration with 4D Molecular Therapeutics (4DMT) because of product safety issues, and this is of particular interest since Pfizer had taken an equity stake in the company in 2016, prior to Pfizer's Covid-19 windfall.
[ This is another example why pelareorep's safety and effectiveness are product benefits that is not being overlooked by both these and other ONCY partners ]
https://www.fiercebiotech.com/biotech/4dmt-will-regain-full-rights-to-blinding-disease-therapy-from-roche-to-initiative-new
.